NASDAQ:STAA

STAAR Surgical - STAA Stock Forecast, Price & News

$60.27

-2.06 (-3.30%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $58.81
▼
$62.31
50-Day Range: $55.30
▼
$76.20
52-Week Range: $49.03
▼
$112.27

Volume: 491,249 shs
Average Volume: 487,515 shs
Market Capitalization: $2.91 billion

P/E Ratio: 79.30
Dividend Yield: N/A
Price Target: $92.89

STAAR Surgical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 54.1% Upside
$92.89 Price Target
Short Interest: Healthy
4.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.08
Based on 5 Articles This Week
Insider Trading: Selling Shares
$2.66 M Sold Last Quarter
Proj. Earnings Growth: 44.00%
From $0.75 to $1.08 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.26 out of 5 stars

Medical Sector

1st out of 1,023 stocks

Ophthalmic Goods Industry

1st out of 7 stocks

4.5

Analyst's Opinion

Consensus Rating
STAAR Surgical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $92.89, STAAR Surgical has a forecasted upside of 54.1% from its current price of $60.27.
Amount of Analyst Coverage
STAAR Surgical has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
4.92% of the outstanding shares of STAAR Surgical have been sold short.
Short Interest Ratio / Days to Cover
STAAR Surgical has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in STAAR Surgical has recently decreased by 22.80%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
STAAR Surgical does not currently pay a dividend.
Dividend Growth
STAAR Surgical does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
STAAR Surgical has received a 58.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Intraocular lenses" product. See details.
Environmental Sustainability
The Environmental Impact score for STAAR Surgical is -0.73.

2.3

News and Social Media Coverage

News Sentiment
STAAR Surgical has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for STAAR Surgical this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for STAA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added STAAR Surgical to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, STAAR Surgical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,656,875.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of STAAR Surgical is held by insiders.
Percentage Held by Institutions
96.38% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for STAAR Surgical are expected to grow by 44.00% in the coming year, from $0.75 to $1.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of STAAR Surgical is 79.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.26.
Price to Earnings Ratio vs. Sector
The P/E ratio of STAAR Surgical is 79.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.13.
Price to Book Value per Share Ratio
STAAR Surgical has a P/B Ratio of 11.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Stock News Headlines

December 2, 2022 | americanbankingnews.com

Short Interest in STAAR Surgical (NASDAQ:STAA) Drops By 22.8%

December 2, 2022 | americanbankingnews.com

STAAR Surgical (NASDAQ:STAA) Price Target Cut to $79.00

November 28, 2022 | finance.yahoo.com

Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

November 28, 2022 | americanbankingnews.com

STAAR Surgical (NASDAQ:STAA) Receives $94.89 Average PT from Analysts

November 28, 2022 | americanbankingnews.com

Brokerages Set STAAR Surgical (NASDAQ:STAA) Target Price at $94.89

November 17, 2022 | finance.yahoo.com

STAAR Surgical Opens EVO Experience Center in United States

November 13, 2022 | finance.yahoo.com

Is Now An Opportune Moment To Examine STAAR Surgical Company (NASDAQ:STAA)?

November 11, 2022 | finance.yahoo.com

Are Options Traders Betting on a Big Move in STAAR (STAA) Stock?

November 3, 2022 | markets.businessinsider.com

What 8 Analyst Ratings Have To Say About Staar Surgical

November 3, 2022 | seekingalpha.com

STAAR Surgical Company (STAA) Q3 2022 Earnings Call Transcript

November 2, 2022 | finance.yahoo.com

Staar Surgical (STAA) Q3 Earnings and Revenues Beat Estimates

November 2, 2022 | markets.businessinsider.com

STAAR Surgical Company Q3 Profit Increases, beats estimates

November 2, 2022 | finance.yahoo.com

STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y

October 29, 2022 | finance.yahoo.com

STAAR Surgical's (NASDAQ:STAA) investors will be pleased with their enviable 465% return over the last five years

October 20, 2022 | nz.finance.yahoo.com

$13+ Billion Contact Lenses Market Size to Grow at a CAGR of 5.1% by 2028 | The Insight Partners

October 19, 2022 | finance.yahoo.com

STAAR Surgical to Report Third Quarter Results on November 2, 2022

October 14, 2022 | markets.businessinsider.com

Tesla To $230? Plus Canaccord Genuity Cuts PT On T2 Biosystems By 80%

October 14, 2022 | nasdaq.com

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Is Well Worth Watching

October 13, 2022 | markets.businessinsider.com

Expert Ratings for Staar Surgical

October 12, 2022 | finance.yahoo.com

Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses

October 7, 2022 | finance.yahoo.com

Is Staar Surgical (STAA) a Solid Growth Stock? 3 Reasons to Think "Yes"

October 2, 2022 | finance.yahoo.com

2 Evergreen Growth Stocks to Buy and Hold Forever

October 2, 2022 | fool.com

STAAR Surgical (NASDAQ: STAA)

September 29, 2022 | marketwatch.com

Ophthalmology Devices Market : Research Report Analysis by Competitors, Sales, Revenue and Industry Size 2022 To 2027

September 29, 2022 | marketwatch.com

Ophthalmology Devices Market 2022 Industry Outlook, Current Status, Supply-Demand, Growth Opportunities and Top Players Analysis 2027

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Company Calendar

Last Earnings: 11/02/2022
Today: 12/06/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Ophthalmic goods
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:STAA
CUSIP: 85231230
CIK: 718937
Web: www.staar.com
Phone: (626) 303-7902
Fax: 626-303-2962
Employees: 692
Year Founded: 1982

Price Target and Rating

Average Stock Price Forecast: $92.89
High Stock Price Forecast: $125.00
Low Stock Price Forecast: $79.00
Forecasted Upside/Downside: +54.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.76
Trailing P/E Ratio: 79.30
Forward P/E Ratio: 80.36
P/E Growth: N/A
Net Income: $24.50 million
Net Margins: 13.54%
Pretax Margin: 16.66%
Return on Equity: 15.13%
Return on Assets: 11.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.55
Quick Ratio: 6.11

Sales & Book Value

Annual Sales: $230.47 million
Price / Sales: 12.61
Cash Flow: $0.64 per share
Price / Cash Flow: 94.33
Book Value: $5.43 per share
Price / Book: 11.10

Miscellaneous

Outstanding Shares: 48,206,000
Free Float: 46,953,000
Market Cap: $2.91 billion
Optionable: Optionable
Beta: 1.00

Social Links

Key Executives

Ms. Caren L. Mason (Age 68)
CEO, Pres & Director
Comp: $1.97M

Mr. Patrick F. Williams (Age 49)
Chief Financial Officer
Comp: $934.82k

Dr. Keith Holliday (Age 59)
Chief Technology Officer
Comp: $822.97k

Mr. Hans-Martin Blickensdoerfer (Age 57)
Consultant
Comp: $756.58k

Dr. Scott D. Barnes M.D. (Age 59)
Chief Medical Officer
Comp: $874.46k

Mr. Brian Moore
VP of Investor, Media Relations & Corp. Devel.

Mr. Samuel J. Gesten (Age 60)
Chief Legal Officer & Corp. Sec.

Mr. James Francese (Age 58)
Sr. VP of Commercial Operations - North America & APAC

Joanne Egamino Ph.D.
Global Head of Clinical Operations

Mr. Philippe Subrin (Age 58)
VP of Collamer Lens Manufacturing & GM of Nidau Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STAA Stock - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STAA shares.
View STAA analyst ratings or view top-rated stocks.
What is STAAR Surgical's stock price forecast for 2023?: 9 brokers have issued 1 year price targets for STAAR Surgical's shares. Their STAA share price forecasts range from $79.00 to $125.00. On average, they expect the company's share price to reach $92.89 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.
How have STAA shares performed in 2022?: STAAR Surgical's stock was trading at $91.30 on January 1st, 2022. Since then, STAA stock has decreased by 34.0% and is now trading at $60.27.
View the best growth stocks for 2022 here.
Are investors shorting STAAR Surgical?: STAAR Surgical saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,370,000 shares, a drop of 22.8% from the October 31st total of 3,070,000 shares. Based on an average trading volume of 458,300 shares, the short-interest ratio is presently 5.2 days.
View STAAR Surgical's Short Interest.
When is STAAR Surgical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our STAA earnings forecast.
How were STAAR Surgical's earnings last quarter?: STAAR Surgical (NASDAQ:STAA) issued its quarterly earnings data on Wednesday, November, 2nd. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.12. The medical instruments supplier earned $76.05 million during the quarter, compared to the consensus estimate of $74.95 million. STAAR Surgical had a trailing twelve-month return on equity of 15.13% and a net margin of 13.54%. The firm's revenue was up 30.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.13 earnings per share.
What guidance has STAAR Surgical issued on next quarter's earnings?: STAAR Surgical updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $285.00 million-$285.00 million, compared to the consensus revenue estimate of $294.94 million.
What is Caren Mason's approval rating as STAAR Surgical's CEO?: 6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).
What is STAAR Surgical's stock symbol?: STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."
Who are STAAR Surgical's major shareholders?: STAAR Surgical's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.61%), Vanguard Group Inc. (10.83%), Baillie Gifford & Co. (10.67%), State Street Corp (3.25%), Palo Alto Investors LP (2.28%) and Geneva Capital Management LLC (1.97%). Insiders that own company stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends.
How do I buy shares of STAAR Surgical?: Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is STAAR Surgical's stock price today?: One share of STAA stock can currently be purchased for approximately $60.27.
How much money does STAAR Surgical make?: STAAR Surgical (NASDAQ:STAA) has a market capitalization of $2.91 billion and generates $230.47 million in revenue each year. The medical instruments supplier earns $24.50 million in net income (profit) each year or $0.76 on an earnings per share basis.
How many employees does STAAR Surgical have?: The company employs 692 workers across the globe.
Does STAAR Surgical have any subsidiaries?: The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More
How can I contact STAAR Surgical?: STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.

This page (NASDAQ:STAA) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial